Cargando…

Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease

Chronic kidney disease, despite being a “silent epidemic” disease, represents one of the main causes of mortality in general population, along with cardiovascular disease, which is the leading cause of poor prognosis for these patients. The specific objective of our study was to characterize the rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Mihai, Simona, Codrici, Elena, Popescu, Ionela Daniela, Enciu, Ana-Maria, Rusu, Elena, Zilisteanu, Diana, Albulescu, Radu, Anton, Gabriela, Tanase, Cristiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030443/
https://www.ncbi.nlm.nih.gov/pubmed/27667892
http://dx.doi.org/10.1155/2016/3185232
_version_ 1782454681012797440
author Mihai, Simona
Codrici, Elena
Popescu, Ionela Daniela
Enciu, Ana-Maria
Rusu, Elena
Zilisteanu, Diana
Albulescu, Radu
Anton, Gabriela
Tanase, Cristiana
author_facet Mihai, Simona
Codrici, Elena
Popescu, Ionela Daniela
Enciu, Ana-Maria
Rusu, Elena
Zilisteanu, Diana
Albulescu, Radu
Anton, Gabriela
Tanase, Cristiana
author_sort Mihai, Simona
collection PubMed
description Chronic kidney disease, despite being a “silent epidemic” disease, represents one of the main causes of mortality in general population, along with cardiovascular disease, which is the leading cause of poor prognosis for these patients. The specific objective of our study was to characterize the relationship between the inflammatory status, the bone disorders markers, and kidney failure in chronic kidney disease patient stages 2–4, in order to design a novel biomarker panel that improves early disease diagnosis and therapeutic response, thus being further integrated into clinical applications. A panel of proteomic biomarkers, assessed by xMAP array, which includes mediators of inflammation (IL-6, TNF-α) and mineral and bone disorder biomarkers (OPG, OPN, OCN, FGF-23, and Fetuin-A), was found to be more relevant than a single biomarker to detect early CKD stages. The association between inflammatory cytokines and bone disorders markers, IL-6, TNF-α, OPN, OPG, and FGF-23, reflects the severity of vascular changes in CKD and predicts disease progression. Proteomic xMAP analyses shed light on a new approach to clinical evaluation for CKD staging and prognosis.
format Online
Article
Text
id pubmed-5030443
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-50304432016-09-25 Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease Mihai, Simona Codrici, Elena Popescu, Ionela Daniela Enciu, Ana-Maria Rusu, Elena Zilisteanu, Diana Albulescu, Radu Anton, Gabriela Tanase, Cristiana Dis Markers Research Article Chronic kidney disease, despite being a “silent epidemic” disease, represents one of the main causes of mortality in general population, along with cardiovascular disease, which is the leading cause of poor prognosis for these patients. The specific objective of our study was to characterize the relationship between the inflammatory status, the bone disorders markers, and kidney failure in chronic kidney disease patient stages 2–4, in order to design a novel biomarker panel that improves early disease diagnosis and therapeutic response, thus being further integrated into clinical applications. A panel of proteomic biomarkers, assessed by xMAP array, which includes mediators of inflammation (IL-6, TNF-α) and mineral and bone disorder biomarkers (OPG, OPN, OCN, FGF-23, and Fetuin-A), was found to be more relevant than a single biomarker to detect early CKD stages. The association between inflammatory cytokines and bone disorders markers, IL-6, TNF-α, OPN, OPG, and FGF-23, reflects the severity of vascular changes in CKD and predicts disease progression. Proteomic xMAP analyses shed light on a new approach to clinical evaluation for CKD staging and prognosis. Hindawi Publishing Corporation 2016 2016-09-07 /pmc/articles/PMC5030443/ /pubmed/27667892 http://dx.doi.org/10.1155/2016/3185232 Text en Copyright © 2016 Simona Mihai et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Mihai, Simona
Codrici, Elena
Popescu, Ionela Daniela
Enciu, Ana-Maria
Rusu, Elena
Zilisteanu, Diana
Albulescu, Radu
Anton, Gabriela
Tanase, Cristiana
Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease
title Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease
title_full Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease
title_fullStr Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease
title_full_unstemmed Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease
title_short Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease
title_sort proteomic biomarkers panel: new insights in chronic kidney disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030443/
https://www.ncbi.nlm.nih.gov/pubmed/27667892
http://dx.doi.org/10.1155/2016/3185232
work_keys_str_mv AT mihaisimona proteomicbiomarkerspanelnewinsightsinchronickidneydisease
AT codricielena proteomicbiomarkerspanelnewinsightsinchronickidneydisease
AT popescuioneladaniela proteomicbiomarkerspanelnewinsightsinchronickidneydisease
AT enciuanamaria proteomicbiomarkerspanelnewinsightsinchronickidneydisease
AT rusuelena proteomicbiomarkerspanelnewinsightsinchronickidneydisease
AT zilisteanudiana proteomicbiomarkerspanelnewinsightsinchronickidneydisease
AT albulescuradu proteomicbiomarkerspanelnewinsightsinchronickidneydisease
AT antongabriela proteomicbiomarkerspanelnewinsightsinchronickidneydisease
AT tanasecristiana proteomicbiomarkerspanelnewinsightsinchronickidneydisease